Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04861194 | EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)(ERECT) | recruiting | N/A | 70 | UMC UtrechtOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06130995 | Relugolix + Enzalutamide Study in High-Risk Prostate Cancer | recruiting | Phase 1 | 46 | University of OklahomaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients(COMBINE) |
| recruiting |
| — |
| 144 |
| University of MiamiOTHER |
| 1 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT05586360 | T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer | recruiting | Phase 2 | 36 | Medical University of South CarolinaOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06171269 | Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life | recruiting | N/A | 60 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07088536 | Occupational Situation and Return to Work of Urological Patients(OCCURORTW) | recruiting | — | 2,000 | Jagiellonian UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07230106 | A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer | recruiting | Phase 2 | 218 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03495427 | PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | recruiting | Phase 2 / Phase 3 | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06237179 | Behavioral Exercise Training to Reduce Cardiovascular Disease Risk(EXTRA-PC) | recruiting | Phase 1 / Phase 2 | 60 | Virginia Commonwealth UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05295407 | Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy(GenBx) | recruiting | — | 1,000 | Endeavor HealthOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05879913 | ASCVD Management Using CCTA in Prostate Cancer Patients on ADT | recruiting | N/A | 100 | Indiana UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07432360 | Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology | recruiting | — | 300 | Virdx, Inc.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | recruiting | Phase 3 | 72 | Emory UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07369570 | Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging(REMRI) | recruiting | N/A | 100 | University of Eastern FinlandOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06267729 | Study of AZD0754 in Participants With Metastatic Prostate Cancer(APOLLO) | recruiting | Phase 1 / Phase 2 | 60 | AstraZenecaINDUSTRY | 3 | Feb 23, 2026 | clinicaltrials |
| NCT06378346 | GU-01: Glycyrrhizin in Prostate Cancer(GU-01) | recruiting | Phase 2 | 60 | University of Illinois at ChicagoOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07285057 | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 120 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426861 | Pre-Operative Nurse-Led Education With Direct Physiotherapy Referral to Reduce Post-Prostatectomy Incontinence(PRO-ACT) | recruiting | N/A | 80 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04354064 | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05720130 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). | recruiting | Phase 1 / Phase 2 | 100 | AdvanCell Pty LimitedINDUSTRY | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05590624 | Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer | recruiting | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06450106 | Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy | recruiting | Phase 1 | 18 | SURGE TherapeuticsINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | recruiting | Phase 2 | 58 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06111313 | The University of Miami Adapt (UAdapt) Trial | recruiting | Phase 2 | 130 | University of MiamiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07339267 | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | recruiting | Phase 1 | 12 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04725903 | Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer | recruiting | N/A | 30 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06052683 | A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer. | recruiting | N/A | 208 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06303622 | Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION Trial | recruiting | N/A | 1,250 | Chinese University of Hong KongOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06990542 | Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer(RadTARGET) | recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07115914 | PSMA PET for Surveillance After Focal Therapy | recruiting | N/A | 62 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407959 | Screening and Staging of Benign vs Malignant Pelvic Abnormalities | recruiting | — | 60 | Mayo ClinicOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03861676 | Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT | recruiting | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05351424 | AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc(ADELANTE) | recruiting | N/A | 194 | Columbia UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06335914 | Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407608 | ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0(ABRUPT 2) | recruiting | — | 58 | University of Milano BicoccaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT07391982 | Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions(DESTINATION 2) | recruiting | N/A | 54 | The Netherlands Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06591819 | Hypofractionated WPPT With HDR Boost | recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06631521 | Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | recruiting | Phase 1 | 30 | AdventHealthOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07001241 | Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | recruiting | Phase 2 | 134 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07276438 | Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial | recruiting | N/A | 186 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07325721 | Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 46 | Medical University of South CarolinaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389512 | Pharmaceutical Management in Targeted Radioligand Therapy(PharmTRT) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | recruiting | Phase 1 | 174 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Feb 4, 2026 | clinicaltrials |
| NCT05810467 | The Active Surveillance Study(AS) | recruiting | — | 200 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06408298 | HCQ in Resectable Localized Prostate Cancer | recruiting | Early Phase 1 | 20 | Lionel.D.Lewis, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial(ID-COMET) | recruiting | Phase 3 | 800 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2026source: clinicaltrials